Business Context and Reporting Period
This Form 8-K, dated January 30, 2024, reports a material definitive agreement between AVROBIO, Inc. ("AVRO") and Tectonic Therapeutic, Inc. ("Tectonic"). The filing details an Agreement and Plan of Merger under which a wholly-owned subsidiary of AVRO will merge with Tectonic, with Tectonic surviving as a wholly-owned subsidiary of AVRO. The transaction is structured as a tax-free reorganization.
Key Financial Metrics and Transaction Terms
- Financing Proceeds: Tectonic is expected to raise approximately $130.7 million in aggregate proceeds through a private placement financing and Simple Agreements for Future Equity (SAFEs) concurrent with the merger.
- Pro Forma Ownership: Assuming the $130.7 million financing, pre-Merger Tectonic stockholders (excluding new financing shares) are expected to own approximately 40.2% of the combined company. Pre-Merger Tectonic stockholders associated with the financing shares are expected to own approximately 37.5%. Pre-Merger AVRO stockholders are expected to own approximately 22.3%.
- Exchange Ratio Adjustments: The exchange ratio may be adjusted if AVRO's net cash at closing is less than $64.5 million or greater than $65.5 million.
- Termination Fees: AVRO may be required to pay Tectonic a termination fee of $2,712,500 and/or reimburse expenses up to $650,000. Tectonic may be required to pay AVRO a termination fee of $4,900,000.
- Cash Conditions: Closing is conditioned on AVRO's net cash not being less than $50,000,000 immediately prior to the Effective Time.
Material Changes and Transaction Structure
The primary material change is the proposed merger of AVRO and Tectonic. Key structural elements include:
- Equity Conversion: Outstanding Tectonic common stock, options, and restricted stock units (RSUs) will convert into AVRO common stock based on the Exchange Ratio.
- AVRO Equity Acceleration: AVRO will accelerate the vesting of in-the-money options for current employees, directors, and consultants, and settle time-based RSUs into shares at closing.
- Reverse Stock Split: AVRO stockholders must approve a reverse stock split of AVRO common stock.
- Board Composition: At closing, one AVRO director will be appointed to the combined company's board, with the remaining directors selected by Tectonic.
Guidance, Outlook, Risks, and Contingencies
Contingent Value Rights (CVRs): AVRO stockholders will receive one CVR for each share held. These rights entitle holders to payments derived from the sale or licensing of specific AVRO assets (plato manufacturing platform, AVR-RD-01/02/03 programs, and certain IP) post-merger. There is no assurance payments will be made.
Closing Conditions: The merger is subject to stockholder approvals from both companies, Nasdaq listing approval, effectiveness of a registration statement, and the successful completion of the $114.5 million minimum financing to Tectonic.
Risks and Uncertainties: The filing highlights significant risks, including the failure to satisfy closing conditions, delays in clinical development for Tectonic's product candidates, inability to secure additional capital, and potential adjustments to the exchange ratio affecting ownership percentages. Forward-looking statements regarding the transaction's timing and the combined company's future operations are subject to these uncertainties.
Investor Verification Checklist
- Verify the final ownership percentages of the combined company once the Exchange Ratio is finalized and financing proceeds are confirmed.
- Confirm the status of the $130.7 million private placement financing and whether the minimum $114.5 million threshold is met.
- Review the upcoming Proxy Statement/Prospectus (Form S-4) for detailed risk factors and the full text of the Merger Agreement.
- Assess the potential value and likelihood of payments under the Contingent Value Rights (CVRs) for existing AVRO shareholders.
- Monitor the approval status of the reverse stock split and the listing of new shares on Nasdaq.